TuHURA Biosciences Receives Nasdaq Delisting Notice for Minimum Bid Price Deficiency

summarizeSummary

TuHURA Biosciences received a Nasdaq delisting notice for failing to maintain a minimum $1.00 bid price, initiating a 180-day grace period to regain compliance.

check_boxKey Events

• Nasdaq Delisting Notice Received

  On January 29, 2026, TuHURA Biosciences, Inc. received a letter from Nasdaq indicating non-compliance with the minimum bid price requirement.

• Minimum Bid Price Deficiency

  The company's consolidated closing bid price has been below $1.00 per share for 35 consecutive business days as of January 28, 2026, violating Nasdaq Listing Rule 5550(a)(2).

• 180-Day Grace Period Granted

  TuHURA Biosciences has been afforded a 180-calendar day grace period, until July 28, 2026, to regain compliance by maintaining a bid price of at least $1.00 for ten consecutive business days.

• Potential Reverse Stock Split

  If a second 180-day grace period is needed, the company would be required to notify Nasdaq of its intention to cure the deficiency, potentially through a reverse stock split.

auto_awesomeAnalysis

TuHURA Biosciences, a micro-cap company, has received a critical notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement. This notice, coming as the stock trades near its 52-week low, signals significant market concern and poses a substantial threat to the company's continued listing on a major exchange. While the company has a 180-day grace period to regain compliance, the need to potentially execute a reverse stock split highlights the precarious position of its stock price and could further impact investor sentiment and liquidity. Failure to regain compliance could lead to delisting, severely limiting the stock's accessibility and potentially accelerating value erosion.